

ong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong  
take no responsibility for the contents of this announcement, make no  
ation as to its accuracy or completeness and expressly disclaim any liability  
for any loss howsoever arising from or in reliance upon the whole or any  
contents of this announcement.



Hepalink

**SHENZHEN HEPALINK PHARMACEUTICAL GROUP CO., LTD.**  
**(深圳市海普瑞藥業集團股份有限公司)**

*(A joint stock company incorporated in the People's Republic of China with limited liability)*

**(Stock code: 9989)**

**ANNOUNCEMENT**

**PROPOSED ISSUANCE OF CORPORATE BONDS  
AND  
CHANGE IN USE OF PROCEEDS**

**PROPOSED ISSUANCE OF CORPORATE BONDS**

On 30 June 2022, the Board (the "Board") of the Company (the "Company") (the "Proposed Issuance" of Corporate Bonds (the "Corporate Bonds") in the PRC), (the "EGM")

**1. ISSUE SIZE**

The total amount of the Corporate Bonds to be issued is B1,000,000,000 (one billion RMB) (the "Issue Size").

**2. TARGET SUBSCRIBERS**

B.

**3. TERM**

B.  
( ).

**4. USE OF PROCEEDS**

( Proceeds- )  
B.

**5. INTEREST RATE**

B.  
B.  
B.

**6. VALIDITY OF THE RESOLUTION(S)**

( ) 24  
B.  
( )

**Reasons and benefits of the Proposed Issuance**

B.  
B.

**PROPOSED CHANGE IN USE OF PROCEEDS**

**Use of Proceeds**

Prospectus-	( )	24	2020 ( )
( Net Proceeds-)	B3,538.4		B
	2020 ( Global Offering-)		
2022 ( Interim Report-),		30	30
2022			

A	30%	(	B1,061.5	)
	30%	(	B1,061.5	)
				20%
		B707.7	(	)
				20%
		B707.7	(	)

A			B1,115.2
	30	2022	
	B2,423.2		

## Proposed Change in Use of Proceeds

B. (Proposed Change in Use of Proceeds)






Business objectives	Original planned use of the Net Proceeds as disclosed in the Prospects (RMB million)	Utilised as at the date of this announcement (RMB million)	Remaining proceeds as at the date of this announcement (RMB million)	Revised allocation of unutilised Net Proceeds (RMB million)	Expected date of full utilisation of the unutilised Net Proceeds
(1) 收购及整合中国境内及境外的优质资产，以扩大公司的经营规模及提升公司的盈利能力。	1,061.5 (30% of the net proceeds)	1,034.4	27.1		
(2) 收购及整合中国境内及境外的优质资产，以扩大公司的经营规模及提升公司的盈利能力。	1,061.5 (30% of the net proceeds)		1,061.5	636.9	24 months
(3) 收购及整合中国境内及境外的优质资产，以扩大公司的经营规模及提升公司的盈利能力。	707.7 (20% of the net proceeds)		707.7	451.8	24 months
(4) 收购及整合中国境内及境外的优质资产，以扩大公司的经营规模及提升公司的盈利能力。	707.7 (20% of the net proceeds)	80.8	626.9	376.2	24 months
(5) 收购及整合中国境内及境外的优质资产，以扩大公司的经营规模及提升公司的盈利能力。				958.3	24 months
	<u>3,538.4</u>	<u>1,115.2</u>	<u>2,423.2</u>	<u>2,423.2</u>	






## Reasons for and benefits of the Proposed Change in Use of Proceeds

2022 -19

B

A

B.  B.  24  A.  B376.2 

2021  2022  2022  -19,  31 

A

A

B

B B  
**Shenzhen Hepalink Pharmaceutical Group Co., Ltd.**  
**Li Li**  
*Chairman*

30 2022

*As at the date of this announcement, the executive directors of the Company are Mr. Li Li, Ms. Li Tan and Mr. Shan Yu; and the independent non-executive directors of the Company are Dr. Lu Chuan, Mr. Chen Junfa and Mr. Wang Zhaohui.*

*\* for identification purposes only*